Saral R, Ambinder R F, Burns W H, Angelopulos C M, Griffin D E, Burke P J, Lietman P S
Ann Intern Med. 1983 Dec;99(6):773-6. doi: 10.7326/0003-4819-99-6-773.
Twenty-nine adult patients with acute leukemia receiving timed sequential chemotherapy participated in a randomized, double-blind, placebo-controlled trial of acyclovir prophylaxis against reactivated herpes simplex virus infection. Patients with pretreatment antibody titers of 1:16 or greater received acyclovir or placebo starting 4 days after their initial chemotherapy. Treatment was given either for 32 days or until the patients were discharged from the hospital or until a culture-positive herpes simplex virus infection was found. Culture-positive herpes simplex virus infection developed in 11 of 15 patients who received placebo. No infection appeared in 14 patients who received acyclovir (p less than 0.00005). No obvious acute drug toxicity was seen. Recurrent infection was seen in 6 of 14 patients after cessation of acyclovir when retreated with chemotherapy, suggesting no effect on viral latency in these 6 patients. Acyclovir provided highly effective prophylaxis against reactivated herpes simplex virus infections in adult patients with acute leukemia receiving timed sequential chemotherapy.
29例接受定时序贯化疗的成年急性白血病患者参与了一项关于阿昔洛韦预防单纯疱疹病毒再激活感染的随机、双盲、安慰剂对照试验。预处理抗体滴度为1:16或更高的患者在首次化疗后4天开始接受阿昔洛韦或安慰剂治疗。治疗持续32天，或直至患者出院，或直至发现培养阳性的单纯疱疹病毒感染。接受安慰剂的15例患者中有11例发生了培养阳性的单纯疱疹病毒感染。接受阿昔洛韦的14例患者未出现感染（p<0.00005）。未观察到明显的急性药物毒性。14例患者在停用阿昔洛韦后再次化疗时，有6例出现复发性感染，提示对这6例患者的病毒潜伏无影响。阿昔洛韦为接受定时序贯化疗的成年急性白血病患者预防单纯疱疹病毒再激活感染提供了高效保护。
